Home-administered pre-surgical psychological intervention for knee osteoarthritis (HAPPiKNEES): study protocol for a randomised controlled trial by das Nair, Roshan et al.
das Nair, Roshan and Anderson, P and Clarke, Simon P. 
and Leighton, P and Lincoln, Nadina and Mhizha-Murira, 
Jacqueline R. and Scammell, Brigitte E. and Walsh, 
David A. (2016) Home-administered pre-surgical 
psychological intervention for knee osteoarthritis 
(HAPPiKNEES): study protocol for a randomised 
controlled trial. Trials, 17 . p. 54. ISSN 1745-6215 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/51916/1/dasNair%20et%20al_Home-administered%20pre-
surgical%20intervention.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
STUDY PROTOCOL Open Access
Home-administered pre-surgical
psychological intervention for knee
osteoarthritis (HAPPiKNEES): study protocol
for a randomised controlled trial
Roshan das Nair1,2*, Pippa Anderson3, Simon Clarke1,4,5, Paul Leighton6, Nadina B. Lincoln1,4,
Jacqueline R. Mhizha-Murira1, Brigitte E. Scammell4 and David A. Walsh4,7
Abstract
Background: Knee replacement surgery reduces pain for many people with osteoarthritis (OA). However, surgical
outcomes are partly dependent on patients’ moods, and those with depression or anxiety have worse outcomes.
Approximately one-third of people with OA have mood problems. Cognitive behavioural therapy (CBT), a psychological
therapy, is recommended by the National Institute for Health and Care Excellence for improving mood. However,
evidence for the effectiveness of CBT before knee surgery in improving pain, mood, and quality of life following this
surgery for people with knee OA is lacking.
Methods/Design: This is a multi-centre, mixed-methods feasibility randomised controlled trial to compare treatment
as usual (TAU) plus a brief CBT-based intervention with a TAU-only control, for people with knee OA. We will recruit 50
patients with knee OA, listed for knee replacement surgery, with high levels of distress (assessed using a
mood questionnaire), and who consent to take part. Participants will be randomly allocated to receive TAU
plus intervention or TAU. Up to 10 sessions of CBT will be offered on an individual basis by a psychologist.
The assessments and interventions will be completed before surgery. Repeat assessments at 4 and 6 months
after randomisation will be sent and received by post.
Two patient-partners will conduct feedback interviews with some participants to assess what aspects of the
intervention were helpful or unhelpful, the acceptability of randomisation, the experience of being in a control
group, and the appropriateness of the measures used. Interviews will be audio-recorded, transcribed, and
analysed using the framework approach. We will examine the feasibility and acceptability of patient-partners
conducting the interviews by also interviewing the patient-partners.
Discussion: Findings from this study will be used to design a definitive study that will examine the clinical and
cost-effectiveness of the CBT intervention in improving patient outcomes following knee surgery.
Trial Registration: Current Controlled Trials ISRCTN80222865; Date: 19 June 2014.
Keywords: Chronic pain, Cognitive behavioural therapy, Knee osteoarthritis, Depression, Anxiety, Quality of life
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Background
Total knee arthroplasty (TKA; or joint replacement sur-
gery) is a common elective procedure for management
of chronic pain in knee osteoarthritis (OA) [1]. The suc-
cess of these operations is associated with various demo-
graphic and clinical factors [2]. Predictors of good
outcome are preoperative pain severity [3], body mass
index, pre-operative mood, and attitudinal factors [4].
Lingard and colleagues [3] reported that preoperative
pain and lower mental health scores were predictive of
worse postoperative pain outcomes. Studies have also
shown that preoperative depression and anxiety were as-
sociated with high pain levels 1 to 2 years after TKA [5,
6]. The prevalence of depression in men and women
with OA are higher than the national average, around
33 % and 23 % respectively [7]. Data from our clinic sug-
gested that 25 % of preoperative patients with knee OA
had a Beck Depression Inventory-II score of above 13.
In addition, 18 % of preoperative patients had a State
Trait Anxiety Inventory-state score of above 50. These
scores suggest that about a third of patients awaiting
TKA experience depressed mood or increased anxiety,
and they may benefit from psychological intervention.
Depression has been found to be strongly associated
with preoperative pain severity [8], and the interaction
between depression and chronic disease can complicate
the treatment of both conditions [9]. People with OA
with higher levels of optimism were more likely to have
positive outcomes (including reduced pain) following
surgery [4, 8]. Psychological distress may impair wound-
healing [8, 10], and also has negative effects on func-
tional outcomes and imposes role limitations in older
patients a year after TKA [11]. Furthermore, concomi-
tant depression is related to worse adherence to medical
care for physical conditions [12] and greater use of pain
medication [13]. The cycle of depression, fatigue, and ac-
tivity avoidance has been recognised [14, 15]. In
addition, comorbidity of depressive and anxiety disorders
is common and has been shown to be a consistent pre-
dictor of chronicity of mood disorders [16].
Together, these studies suggest that preoperative
emotional functioning is associated with postoperative
pain and that a reduction in anxiety and depression
pre-operatively may lead to improved post-operative
outcomes.
There is a theoretical rationale, which is supported by
research [4, 17, 18], for assuming that improving mood
and attitudes towards surgery will result in better post-
operative outcomes. For instance, studies have shown
the relationship between psychological factors and
wound healing, with higher anxiety and stress levels as-
sociated with greater postsurgical pain, and with pain
having an effect on immune function and wound healing
[17]; mood and attitudinal factors have been found to be
associated with surgical outcomes, length of hospital
stay, functional recovery, and patient self-report ratings
of recovery [4]. However, the interventions used to ad-
dress these psychological factors have been limited to
‘information giving’ preoperative classes [19–21]. None
of these studies have examined the long-term impact of
the intervention, nor have they examined mood-related
pain and quality of life as outcomes. Furthermore, none
of these studies have examined the cost-effectiveness of
delivering psychological interventions in improving sur-
gical outcomes.
Cognitive Behavioural Therapy (CBT) is a psycho-
logical treatment that has shown to be effective in treat-
ing depression and anxiety, and is considered a
treatment of choice for these conditions by the National
Institute for Health and Clinical Excellence [22]. TKA is
a relatively costly intervention; based on the knee
arthroplasty trial [23] on average, primary TKA and
5 years of subsequent care cost £7458 per patient (SD:
£4058), although the benefits in terms of quality-
adjusted life years (QALYs) are relatively large, with pa-
tients gaining an average of 1.33 (SD: 1.43) QALYs gen-
erating an incremental cost effectiveness ratio (ICER) of
£5,623 per QALY gained [23, 24]. Improving the out-
comes of TKA increases the value of the intervention to
the patient and the NHS. However, there is limited re-
search that demonstrates the clinical and cost-
effectiveness of a short-term preoperative CBT-based
intervention to improve postoperative TKA outcomes
[25, 26]. Furthermore, there is limited research on
patient-partner involvement in data collection and ana-
lysis in such studies. Therefore, evaluating this aspect
within a feasibility trial may elucidate the potential chal-
lenges and benefits of such patient-partner engagement
before attempting to implement this in a definitive trial.
Methods/Design
Trial objectives
The primary objective is to determine the feasibility of
conducting the trial in line with the study protocol. The
results will indicate the sample size and design of a
definitive study.
Secondary objectives are to determine the following:
1. Rates of recruitment and retaining participants
through the trial.
2. Acceptability of CBT for those awaiting knee surgery
for OA-related pain.
3. Appropriateness of inclusion/exclusion criteria;
acceptability of baseline and outcome measures,
audio recording of sessions, and randomisation
protocol from participants’ perspectives.
4. Sample-size needed for a fully powered Phase III
randomised controlled trial (RCT).
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5. The content of ‘treatment as usual’ (TAU), in order
to describe this for this and future studies.
6. The content of the intervention, to inform the
development of a treatment manual, by time-
sampling the content of therapy.
7. The feasibility and acceptability of patient-partner
led interviews and patient-partner participation in
interview data analysis.
8. The feasibility of collecting data for an economic
evaluation using a service-use questionnaire and
understanding the main cost drivers.
9. Feasibility of conducting the interventions within
existing patient pathways, that is, before TKA.
Trial design
This is a multi-centre, mixed-methods feasibility RCT to
compare TAU plus a brief CBT-based intervention with
a TAU-only control with people with knee OA.
Site and participant recruitment
Participants will be recruited from knee surgery path-
ways at two National Health Service (NHS) hospitals at
the point when they are listed for TKA.
We will use two ways of recruiting participants: either
a member of the orthopaedic clinical team will identify
potential participants at the point of listing for TKA and
will send out an invitation letter and participant infor-
mation sheet inviting patients to complete the Hospital
Anxiety and Depression Scale (HADS) and return it in a
pre-paid return envelope, or the consultants and nurses
will inform patients listed for TKA surgery about this
study during the patients’ clinic appointments. If the pa-
tient expresses interest in finding out more, he or she
will be referred to the research nurse or research associ-
ate (RA), who will explain the study, and go through the
information sheet with them. The patient will be given
the opportunity to ask questions about the study. The
patient will be given some time alone or with the person
accompanying them to consider the information, with-
out the research nurse or RA being present. Patients will
then be given the option to complete the questionnaires
at that point or they will be given the reply slip, screen-
ing questionnaire, participant information sheet, and a
self-addressed envelope to take away with them and post
back.
Recruitment is planned to cover a 12-month period.
Informed consent
Written informed consent will be obtained by the RA or
research nurse before the participant enters the trial.
Participants will have more than 24 hours before they
are randomised; therefore, no treatment will begin be-
fore they have had 24 hours to consider the information.
Participants will be informed that their participation is
entirely voluntary, and they are free to withdraw at any
time. In the event of their withdrawal, any data collected
up until that point will be kept by the research team.
Participants will also be asked to allow the research team
access to their medical notes to obtain information on
their clinical diagnosis and other medical conditions.
They will be asked whether they consent to a feedback
interview to assess the acceptability of the intervention
and will be informed that if allocated to the intervention
group, sessions may be digitally recorded to ensure treat-
ment fidelity. The General Practitioners (GPs) and
orthopaedic consultants of the consenting participants
will be sent a letter to inform them of their patients’ in-
volvement in the trial.
Inclusion criteria
Patients will be eligible to join the trial if they i) are over
the age of 18 years, ii) are listed for TKA surgery, iii)
have OA of the knee, defined and scored radiologically
using European League Against Rheumatism (EULAR
[27]) criteria and line atlas, and iv) are reporting depres-
sion or anxiety as assessed on the HADS [28] (anxiety or
depression subscale score > 7, based on Axford et al.
[29]), which performs well for screening [30].
Exclusion criteria
Potential participants will be excluded if they i) have se-
vere co-morbid psychiatric conditions, as reported by
patients or their carers (for example, dementia, or psych-
osis) and subsequently confirmed by checking medical
notes; ii) have inflammatory arthritis (for example,
rheumatoid arthritis, psoriatic arthritis, or gout); iii) are
unable to provide informed consent; iv) are currently re-
ceiving psychological interventions for their mood prob-
lems (we will not exclude those on medication for their
mood problems, but will record this information); and v)
are unable to communicate in English, as the assess-
ments have been standardised in English and the inter-
vention is being delivered in English.
Initial screening assessment
Initial screening for levels of depression and anxiety
using the HADS will occur either face-to-face with the
RA or research nurse or when participants return the
HADS questionnaire and reply slip.
Baseline assessment
After initial screening on the HADS, the following stan-
dardised questionnaires will be conducted to assess
mood, pain, quality of life, and functional ability:
 Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) [31] to assess the
pain, stiffness, and physical function.
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 Intermittent and Constant Osteoarthritis Pain scale
(ICOAP) [32] to assess pain.
 Beck Depression Inventory (BDI) [33] to assess the
level of depression.
 Beck Anxiety Inventory (BAI) [34] to assess the level
of anxiety.
 EQ-5D™ (The Euroqol Group) [35] to assess the
health-related quality of life.
 Service-use questionnaire (SUQ) to assess the use of
NHS and social services.
The WOMAC and ICOAP assess different aspects of
pain. The ICOAP assesses intermittent and constant
pain, whereas the WOMAC assesses pain, stiffness, and
physical functioning. Possible score ranges for the
ICOAP constant pain and intermittent pain subscales
are 0 to 20 and 0 to 24, respectively, with higher scores
indicating higher pain experienced. Possible ranges for
the three WOMAC subscales are pain (0 to 20), stiffness
(0 to 8) and physical function (0 to 68), with higher
scores indicating more extreme pain, stiffness, and phys-
ical function limitations. The BDI and BAI are measures
of the severity of mood disorder, and total scores range
from 0 to 63 with higher scores suggesting severe de-
pression or anxiety. The EQ-5D™ is a standardised in-
strument for use as a measure of health outcome. It is
applicable to a wide range of health conditions and
treatments; it provides a simple descriptive profile and a
single index value for health status. The EQ-5D is pri-
marily designed for self-completion by respondents and
is ideally suited for use in postal surveys, in clinics, and
face-to-face interviews. It is cognitively simple, taking
only a few minutes to complete. Instructions to respon-
dents are included in the questionnaire. The output
from the questionnaire provides a simple descriptive
profile and a single index value, which are used for
health economic evaluation to enable estimation of qual-
ity adjusted life years. It is applicable to a wide range of
health conditions and treatments. This study is using the
five-level response category version. The ICOAP is rec-
ommended by the Osteoarthritis Research Society Inter-
national, and has been Rasch analysed [36]. The Beck
inventories are recommended in the Quality and Out-
comes Framework guidance [37] and used extensively in
OA research. These standardised assessments were se-
lected because they have adequate psychometric proper-
ties, have been employed in other trials with this patient
group, and map onto the areas our patient and public
involvement (PPI) group felt were most important for
people with knee OA. The SUQ is not a validated ques-
tionnaire but is based on standard practice and the re-
sources available in the DIRUM database adapted for
use in this study by health-economists, which includes
the number and types of primary and secondary care
NHS resources use (for example, (re)admissions, medi-
cation use, travel costs) and changes to employment sta-
tus. The SUQ has been developed for the study to
collect the use of NHS and social services resources by
the participant during the study period.
Randomisation
After baseline assessments, individual randomisation will
be conducted by an independent party not otherwise in-
volved with the study, using a computer-generated ran-
dom code. Participants will be randomly allocated to the
CBT plus TAU or TAU alone on a 1: 1 ratio.
Sample size and justification
As this is a feasibility study, we will continue to ap-
proach and recruit people until we have randomised at
least 50 participants (25 to each group). This should
provide us with sufficient information to inform the de-
sign of a Phase III RCT, as the recommended sample
size for feasibility trials is 12 participants per group [38].
Intervention group
The intervention group will receive up to 10 sessions of
CBT, based on general principles of CBT for anxiety and
depression, and pain management, tailored to the spe-
cific needs of each participant. This is not standardised
as this is a feasibility trial, so we need the flexibility to
determine what is appropriate. Participants will not all
require the same number of sessions because they will
not all have the same severity of problems. There are no
standardised protocols for CBT for osteoarthritis or pre-
surgical preparation for OA, so a key part of the feasibil-
ity trial is to establish the treatment protocol. The CBT
sessions will be offered by a psychologist, trained in de-
livering CBT-based interventions, in the participant’s
home or in clinic. Some participants prefer to be seen in
hospital, and some prefer to be seen at home. As this is
a feasibility trial, we plan to offer the flexibility to do ei-
ther so we can determine what people generally prefer.
In addition, due to disability issues, some participants
may struggle to make it regularly to the clinic, and by
offering home sessions, we are being more inclusive.
Sessions will be once or twice weekly and last approxi-
mately one hour. The content of the intervention will
combine the core elements of CBT for pain management
outlined by Gatchel et al. [39], Morley [40], and the
Gloucester Pain Management Manual [41], namely: psy-
choeducation on mood and pain (for example, pain pro-
cessing, the relation between pain and stress, the CBT
approach to self-management, etcetera); values-based
goal-setting; self-management and behavioural activation
(e.g. diet, exercise, activity planning, pacing, etcetera);
relaxation and mindful breathing (including instruction
on the fight/flight response); cognitive restructuring
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(including identifying negative automatic thoughts,
changing negative thinking patterns, and challenging
maladaptive beliefs); and post-surgical planning (for ex-
ample, acceptance of rehabilitation time-scales and
adaption of coping strategies). The therapy sessions will
be audio recorded. These sessions will fit within the ex-
pected waiting time for surgery (18 weeks).
Control group (treatment as usual)
Control group participants will receive treatment as
usual (TAU). They will not receive any therapeutic input
from the psychologist.
All other clinical services will be provided as usual for
both groups. Any additional input (including medical or
psychological interventions) participants receive during
the study will be recorded on the SUQ.
Compliance with interventions
The psychologist will record the number of treatment
sessions participants receive. To ensure the fidelity of
the intervention, the content of the treatment sessions
will be digitally recorded, transcribed and analysed.
Time-sampling, based on minute-by-minute coding of
content, and saliency analysis of the intervention tran-
scripts will enable us to document the content and deliv-
ery of the intervention. This will enable us to further
develop the manual for the Phase III RCT.
Participant outcome measures
Participants from both groups will be assessed 4 and
6 months after randomisation, using the same assess-
ments as at baseline. Paper-based questionnaires includ-
ing the outcome measures will be sent to participants by
post, with a pre-paid return envelope. If participants
have difficulty completing the measures, they will be
able to request help by telephone from the RA. As far as
is feasible, medication prescribed will be checked in the
patients’ hospital notes and compared to findings from
the SUQ and any critical discrepancies will be noted.
This exercise will inform the development of the SUQ
for the main study.
Minimisation of bias
The participants will not be blind to the allocated inter-
vention. Outcome assessments will include self-report
questionnaires, which will be sent to participants by post
and will be received by the RA who will remain blind to
group allocation. To prevent unblinding, the RA will re-
quest participants not to discuss any aspect of being in-
volved with the study. The RA will also be required to
guess the treatment allocation for each participant (that
is, whether they are ‘intervention’ or ‘TAU’), and this will
be compared later to the actual allocation to determine
the degree of unblinding. As participants will know to
which group they were allocated, observer-outcome
blinding will be possible.
Participant feedback interviews
Up to 30 participants (15 from the intervention and 15
from the TAU groups) will be invited to take part in a
brief semi-structured feedback interview conducted by
the RA. Selection will be purposive to capture data from
both ‘typical’ participants (complete the intervention, no
complications, etcetera) but also from those who experi-
ence difficulties with therapy or research process, com-
plications and/or drop out of the study. Thirty is a
manageable number to interview in the context of a
study of this size, and a total population of 30 should
provide sufficient data to be confident in the study find-
ings. Moreover, prior research has identified that data sat-
uration occurs after approximately 12 interviews [42, 43],
which means that we might consider intervention and
TAU groups as distinct data sets if we wish to draw con-
clusions about one side of the study or other. Up to 10 of
these interviews will be conducted by trained and sup-
ported patient-partners, who will be requested to keep a
research diary of their experiences, including the chal-
lenges of conducting these interviews. We believe this
patient-partner activity is appropriate because some par-
ticipants may feel more comfortable talking freely about
their experiences of the study/intervention with someone
who has prior experience of the same health condition,
and because this person will have greater independence
from the academic research team. We will provide train-
ing and support for patient-partners and allocate funding
to cover these costs.
These interviews will offer intervention participants an
opportunity to report on what they found useful or un-
helpful about the intervention, the content, and delivery
(including format and ‘dose’ of treatment). Control
group participants’ interviews will explore their feelings
about not receiving the intervention and to ascertain the
acceptability of randomisation. For both groups we will
make inquiries about the services they received to add
to and contextualise the information collected from the
SUQ. This will enable us to describe the TAU. All inter-
viewed participants will be asked about the research
process, focussing on recruitment, randomisation, and
outcome measures.
Duration of participant participation
Figure 1 shows the expected progress of the study. Each
participant is expected to be in the study for approxi-
mately 8 months, including 6-month follow-up ques-
tionnaires and qualitative interviews. Participants will
leave the study when they have completed the 6-month
follow-up. See the Trial CONSORT Diagram in Fig. 1.
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Data analysis
The outcomes map onto the aims of the feasibility study
(see Table 1) and will be assessed in the following three
ways:
1. Individual feedback interviews with study
participants
The interview data generated will be subject to a
framework analysis (see below). We will also
compare the content of interviews conducted by
patient-partners and the RA. Two researchers (RdN
and PL) will review anonymised interview transcripts
to ensure the quality and consistency of the interview
data across the sample.
2. Completion of outcome assessments and evaluation
of intervention content and delivery
Rates of meeting eligibility criteria, recruitment,
consent, completing treatments, and completing
outcome questionnaires will be described/reported
in the CONSORT diagram. We will also record
what data was found to be missing from the
outcome questionnaires and whether this missing
information was obtained with telephone follow-up.
This method of reducing missing data has been
found useful in other studies [44]. These data (and
information from participant interviews) will also
indicate any problems with outcome questionnaires
being sent by post. The scores from the questionnaires
will enable us to compute sample-size and power
calculations for the future Phase III RCT. The
feasibility of using the SUQ will also be assessed by
examining rates of completion. By recording the
dates of recruitment, randomisation, surgery, and
keeping treatment attendance records, we will be
able to assess how the intervention fits within the
existing patient pathway.
Time-sampling, based on minute-by-minute
coding of content, and saliency analysis of
intervention recordings will enable us to
document the content and delivery of the
intervention. This will help us develop the final
manual for the Phase III RCT.
Fig. 1 CONSORT diagram. The CONSORT diagram illustrates and reports the progression of the participants through the different points of the study
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Table 1 Trial objectives, outcome measures and sources of data. For each trial objective, the outcome measure to be reported and
the sources of the data are described. Trial source data include screening and recruitment logs, CONSORT diagram, and case report
forms at the different time points (baseline, 4 months follow-up (1) and 6 months follow-up (2))
Objectives Outcome measures Data source
1. Rates of recruitment and retaining participants
through the trial
The number of patients listed for TKA
surgery
Screening logs
Study CONSORT diagram (screening)
Number of patients recruited (giving
consent) and
Recruitment logs
Study CONSORT diagram (randomisation)
Number completing follow-up 1 Recruitment logs
Study CONSORT diagram (follow-up 1)
Number completing follow-up 2 Recruitment logs
Study CONSORT diagram (follow-up 2)
Number withdrawing from the trial Recruitment logs
Study CONSORT diagram (randomisation, follow-up
1 and 2)
2. Acceptability of CBT for those awaiting knee
surgery for OA-related pain
Number of participants receiving the
intervention
Treatment records
Study CONSORT diagram (randomisation - received
allocated intervention)
Number of sessions completed Treatment records
Number of participants who did not receive
allocated treatment (that is, did not start
treatment and discontinued treatment)
Treatment records
Study CONSORT diagram (randomisation - did not
receive allocated intervention; follow-up - discon-
tinued intervention)
Participant views of treatment Participant feedback interviews.
3a. Appropriateness of inclusion/exclusion criteria Scores and rates of mood problems at
screening
Screening questionnaires
Study CONSORT diagram - number not meeting
study inclusion criteria
Participants’ medical notes
3b. Acceptability of baseline and outcome
measures
Rates of completion of questionnaires Study CONSORT diagram – Follow-up (number of
questionnaires returned and number lost to follow-
up at 4 and 6 months after randomisation)
Amount of missing items from
questionnaires and whether this data was
obtained with telephone follow-up
Outcome questionnaires
Specific items consistently missed from
questionnaires
Outcome questionnaires
Ease of answering outcome questionnaires Participant feedback interviews
3c. Audio recording of sessions Number of participants consenting to
sessions being audio recorded
Consent forms
Number of participants consenting to be
randomised
Study CONSORT diagram (randomisation)
3d. Randomisation protocol from participants’
perspectives
Participants’ views of the randomisation
protocol
Participant feedback interviews
4. Sample-size needed for a fully powered Phase
III randomised controlled trial (RCT)
Power and sample size calculations based
on descriptive statistics
Quantitative data: baseline and outcome measures
5. The content of ‘treatment as usual’ (TAU), in
order to describe this for this and future studies
TAU for SFH and NUH Participant feedback interviews
Data from the service use questionnaire (SUQ)
6. The content of the intervention to inform the
development of a treatment manual by time-
sampling the content of therapy
Time-sampling (minute by minute coding of
content)
Treatment audio recordings
Saliency of analysis of intervention
transcripts
Treatment audio recordings
Participant feedback interview transcripts
Study monitoring database
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3. In-depth individual interview and research diary
evaluation with the patient-partners
The effectiveness of this participatory research
model will be evaluated through an examination of
the research diaries, and through an in-depth interview
with patient-partners (conducted by RdN or PL). These
interviews will also be audio recorded and transcribed
verbatim.
Qualitative analyses
Qualitative data will be analysed using a framework ap-
proach [45–47]. This is a hierarchical, matrix-based
method developed for applied qualitative research. It is
particularly suited to research where the goals are clearly
defined at the onset, for example, to support the devel-
opment of a future trial. An initial thematic framework
will be constructed from the interview objectives and
existing literature (for example, literature on clinical trial
recruitment and randomisation in research). The inter-
view data will then be mapped onto this framework, and
the framework will be amended if required to include
new concepts introduced during the interviews. After all
the data have been ‘charted’ in this manner, tables/matri-
ces will be used to summarise each main theme and
interpreted to address the interview objectives. Study
participant interviews will be analysed in conjunction
with the patient-partners. The draft thematic framework
for the participant interviews will be fed back to the PPI
steering group for their comments. We will incorporate
their comments in the final analysis of the thematic
framework. Elements of the thematic framework identi-
fied will be substantiated with anonymised participant
quotes.
Quantitative analysis
For the quantitative data, we will use descriptive statistics
(using the statistical software package SPSS version 21) to
describe the outcomes, and to inform power and sample
size calculations for a future definitive study. Based on the
characteristics of the data, appropriate parametric or non-
parametric statistics will be used. All tests will be two-
sided with an alpha level of 0.05.
Health economics evaluation
Descriptive analyses will be undertaken of both the EQ-
5D™ responses (scored using the algorithm provided by
the developers and the visual analogue scale scores) and
SUQ data. Estimates of the cost of providing the inter-
vention, the main cost drivers in terms of health care re-
source use, the impact of receiving the intervention
prior to TKA on EQ-5D™ and quality adjusted life years
will be presented. We will make estimates of the cost ef-
fectiveness of the intervention expressed as an incre-
mental cost effectiveness ratio together with exploration
of the impact of uncertainty. These analyses will be im-
portant for informing the main study data collection and
the methodological challenges for undertaking a full
economic evaluation.
Assessment of safety and adverse events
The occurrence of adverse events as a result of partici-
pation within this study is not expected, since the trial
involves the use of an evidence-based psychological
intervention delivered by a suitably qualified psycholo-
gist. Therefore, no adverse event data will be collected.
If a patient is identified as suicidal, usual clinical proce-
dures will be followed by the clinical team responsible
for the patient’s care.
If a potential participant is identified as having a high
score on the HADS (>15) at baseline, we will recommend
that they contact their GP to discuss this further. If a par-
ticipant scores high on Question 9 on the BDI (‘I would
kill myself if I had the chance’), a risk assessment will be
undertaken, and we will advise them to discuss this score
Table 1 Trial objectives, outcome measures and sources of data. For each trial objective, the outcome measure to be reported and
the sources of the data are described. Trial source data include screening and recruitment logs, CONSORT diagram, and case report
forms at the different time points (baseline, 4 months follow-up (1) and 6 months follow-up (2)) (Continued)
7. The feasibility and acceptability of patient-
partner led interviews, and patient-partner par-
ticipation in interview data analysis
Number of participants consenting to be
interviewed by a patient-partner
Perceived challenges of conducting
interviews
Patient-partner research diaries
Views on the effectiveness of this
participatory research model
In-depth interviews with patient partners
Quality and consistency of interview data Interview transcripts
8. The feasibility of collecting data for an
economic evaluation using a service-use ques-
tionnaire and understanding the main cost
drivers
Rates of completion Service-use questionnaire
Participant views of questionnaire items Participant feedback interviews
9. Feasibility of conducting the interventions
within existing patient pathways, that is, before
TKA
Number of participants who do not
complete treatment before their surgery
date
Treatment attendance records
Study CONSORT diagram
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with their GP or contact the appropriate crisis team. This
will not affect their participation in the study. If, however,
they have been offered psychological therapy by routine
NHS clinical services at the time of assessing eligibility,
they will not be eligible for inclusion. In practice, this is
unlikely, given the long waiting times for people to receive
such therapies. If they are unable to participate in the trial
treatment, this will indicate the upper limit of distress
which may need to be applied as an exclusion criterion in
future studies. In the unlikely event that a participant is
found to have a suicidal risk, the recruiting NHS Trust’s
standard suicide risk protocol will apply.
The patient-partners will have full UK Disclosure and
Barring Service (DBS) clearance. Home visits will be
conducted in accordance with our Trust’s lone working
policy.
Participants who withdraw
Participants will be informed that they are free to with-
draw from the study at any time without it affecting
their usual health care or legal rights. Participants will
be withdrawn from the study if consent is withdrawn.
However, they will be made aware that data collected be-
fore their withdrawal cannot be destroyed and may still
be used in analysis but no identification will be possible.
If a participant indicates a wish to withdraw from the
intervention, we will enquire whether they will consider
completing the primary outcomes. Participants who
withdraw from the study will not be replaced, but with-
drawal rates and reasons for withdrawal (where pro-
vided) will be recorded. Some participants may be
unable to complete all therapy sessions. This informa-
tion will be recorded.
Withdrawal from this therapy is not considered a
safety issue for participants.
Criteria for terminating the study
The trial will not be terminated unless instructed by the
funder, sponsor, or ethics committee, but failure to com-
ply with treatment will be recorded as an outcome.
Trial management
A Trial Management Group (TMG) (TMG: das Nair,
Lincoln, Scammell, Walsh, Clarke, Anderson and
Mhizha-Murira) will meet fortnightly in the first
2 months and thereafter monthly to ensure that mile-
stones are achieved. The progress of the study will be
monitored by the Arthritis Research UK Pain Centre
management group (who meet every 4 months), which
is chaired by Walsh and includes other members of the
Pain Centre staff with clinical expertise in arthritis and
pain. They have agreed to act as an advisory group.
Finally, the progress of the study will also be reported to
the PPI Advisory Panel at four meetings over the course
of the study through one of our patient-partners on this
study.
The RA will be project manager and will be supervised
by the Chief Investigator (CI). The CI has overall re-
sponsibility for the study and shall oversee all study
management.
Definition of a protocol deviation
A protocol deviation is an unintentional or unantici-
pated departure from the expected conduct of a study
that is inconsistent with the protocol, consent docu-
ments, or other study procedures. All protocol devia-
tions will be recorded by the PIs, and the CI will be
notified.
Ethical approval
Ethical approval was obtained from the NRES Committee
East Midlands – Nottingham 1 on 20.03.2014 (ref: 14/
EM/0099).
Discussion
This study was conceptualised in response to a themed
call for ‘surgical research’ from the National Institute for
Health Research in 2012 and in response to the
expressed need from our patients.
We anticipate that one of the biggest challenges to re-
cruit to this study will be the precise timing of surgery
in relation to when patients are first listed for TKA. Be-
cause we have a limited window in which to complete
the therapy sessions, a considerable amount of flexibility
would be required from both the participants and the
therapist. They will need to work flexibly throughout the
week, in order to cater to participants’ availability. Fur-
thermore, as TKA is an ‘elective’ surgical procedure,
some patients may have or may choose to have their sur-
gery postponed. If this happens after randomisation,
there may be issues in delivering the intervention and
collecting follow-up data, particularly if this coincides
with the participant having the surgery (and associated
pain or discomfort) at that time. However, as a feasibility
trial, these are some of the issues that we hope to under-
stand better to inform the design of a Phase III RCT.
Trial status
The first site was open to recruitment on 4 July 2014, and
the first participant consented on 21 July 2014. The
second site was open to recruitment on 7 August 2014
and the first participant there was consented on 1 October
2014. At the time of preparing this manuscript, 41 people
have been consented and randomised. Recruitment is due
to finish at the end of June 2015.
Abbreviations
CBT: cognitive behaviour therapy; CI: chief investigator; GP: general
practitioner; HADS: hospital anxiety and depression scale; NHS: National
das Nair et al. Trials  (2016) 17:54 Page 9 of 11
Health Service; OA: osteoarthritis; PI: principal investigator at a local centre;
PPI: patient-public involvement; RA: research associate; RCT: randomised
controlled trial; SUQ: service use questionnaire; TAU: treatment as usual;
TKA: total knee arthroplasty; TMG: Trial Management Group.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RdN and NBL conceived the trial, which was developed in collaboration with
the remainder of the authors. PA developed the health economics plan. DW
and BS provided input into the medical and surgical aspects of the study. PL
provided advice on the qualitative data collection and analysis plan. SC
developed the draft treatment manual with RdN and NBL. JMM was
responsible for co-ordinating the study. All authors contributed to the
writing of this manuscript and have agreed to the final version.
Acknowledgements
This research is being organised and sponsored by the Nottingham
University Hospitals NHS Trust, in partnership with the Arthritis Research UK
Pain Centre at the University of Nottingham, and is funded by National
Institute for Health Research - Research for Patient Benefit (NIHR– RfPB;
PB-PG-0712-28076). The views and opinions expressed herein are those of
the authors and do not necessarily reflect those of the NIHR-RfPB, NHS or
the Department of Health.
Author details
1Division of Rehabilitation & Ageing, Queens Medical Centre, University of
Nottingham, Nottingham NG7 2UH, UK. 2Department of Clinical Psychology
& Neuropsychology, Nottingham University Hospitals NHS Trust, Nottingham
NG7 2UH, UK. 3Swansea Centre for Health Economics, College of Human and
Health Sciences, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
4Arthritis Research UK Pain Centre, Clinical Sciences Building, City Hospital,
Nottingham NG5 1 PB, UK. 5Physical Health Clinical Psychology Services,
Nottinghamshire Healthcare NHS Trust, Pain Management Suite, Clinic 9,
King’s Mill Hospital, Mansfield NG17 4JL, UK. 6School of Medicine, University
of Nottingham, Room 2104, C Floor South Block, Queen’s Medical Centre,
Nottingham NG7 2UH, UK. 7Academic Rheumatology, University of
Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1 PB,
UK.
Received: 24 June 2015 Accepted: 11 January 2016
References
1. National Joint Registry for England and Wales. 7th Annual Report. 2010.
2. Katz JN, Barrett J, Mahomed NN, Baron JA, Wright RJ, Losina E. Association
between hospital and surgeon procedure volume and the outcomes of
total knee replacement. J Bone Joint Surg. 2004;86:1909–16.
3. Lingard EA, Katz JN, Wright EA, Sledge CB. Predicting the outcome of total
knee arthroplasty. J Bone Joint Surg. 2004;86:2179–86.
4. Rosenberger PH, Jokl P, Ickovics J. Psychosocial factors and surgical
outcomes: an evidence-based literature review. J Am Acad Orthop Surg.
2006;14:397–405.
5. Brander VA, Stulberg SD, Adams AD, Harden RN, Bruehl S, Stanos SP, et al.
Ranawat Award Paper: Predicting Total Knee Replacement Pain: A
Prospective, Observational Study. Clin Orthop Relat Res. 2003;416:27–36.
6. Lingard EA, Riddle DL. Impact of psychological distress on pain and
function following knee arthroplasty. J Bone Joint Surg. 2007;89:1161–9.
7. Theis KA, Helmick CG, Hootman JM. Arthritis burden and impact are greater
among U.S. women than men: intervention opportunities. J Womens
Health. 2007;16:441–53. doi:10.1089/jwh.2007.371.
8. Rosenberger PH, Kerns R, Jokl P, Ickovics JR. Mood and attitude predict pain
outcomes following arthroscopic knee surgery. Ann Behav Med. 2009;37:70–6.
9. Yohannes AM, Baldwin RC. Medical comorbidities in late-life depression.
Psychiatr Times. 2008;25:197–203.
10. Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Depressive symptoms
predict mucosal wound healing. Psychosom Med. 2007;69:597–605.
11. Faller H, Kirschner S, König A. Psychological distress predicts functional
outcomes at three and twelve months after total knee arthroplasty. Gen
Hosp Psychiatry. 2003;25:372–3.
12. Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med.
2008;121:S8–15.
13. Chrischilles E, Lemke J, Wallace R, Drube G. Prevalence and characteristics of
multiple analgesic drug use in an elderly study group. J Am Geriatr Soc.
1990;38:979–84.
14. Rosemann T, Backenstrass M, Joest K, Rosemann A, Szecsenyi J, Laux G.
Predictors of depression in a sample of 1,021 primary care patients
with osteoarthritis. Arthritis Care Res. 2007;57:415–22. doi:10.1002/art.
22624.
15. Rosemann T, Gensichen J, Sauer N, Laux G, Szecsenyi J. The impact of
concomitant depression on quality of life and health service utilisation in
patients with osteoarthritis. Rheumatol Int. 2007;27:859–63.
16. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, Van Balkom A,
et al. Comorbidity patterns of anxiety and depressive disorders in a large
cohort study: the Netherlands Study of Depression and Anxiety (NESDA).
J Clin Psychiatry. 2011;72:341–8.
17. Kiecolt-Glaser JK, Page GG, Marucha PT, MacCallum RC, Glaser R.
Psychological influences on surgical recovery: perspectives from
psychoneuroimmunology. American Psychol. 1998;53:1209.
18. Munafò MR, Stevenson J. Anxiety and surgical recovery: Reinterpreting the
literature. J Psychosom Res. 2001;51:589–96.
19. Mancuso CA, Graziano S, Briskie LM, Peterson MG, Pellicci PM, Salvati EA,
et al. Randomized trials to modify patients’ preoperative expectations of hip
and knee arthroplasties. Clin Orthop Relat Res. 2008;466:424–31.
20. Prouty A, Cooper M, Thomas P, Christensen J, Strong C, Bowie L, et al.
Multidisciplinary patient education for total joint replacement surgery
patients. Orthop Nurs. 2006;25:257–61.
21. Suva D, Lübbeke A, Hudelson P, Lataillade L, Hoffmeyer P. Patient
information before hip replacement: positive effects of group-session
patient education prior to total hip replacement. Rev Med Suisse.
2007;3:2878–81.
22. National Institute for Health & Clinical Excellence (NICE). Depression in
adults: recognition and management. 2009. https://www.nice.org.uk/
guidance/CG90/chapter/1-Guidance. Accessed 20 Jan 2016.
23. Johnston L, MacLennan G, McCormack K, Ramsay C, Walker A. The Knee
Arthroplasty Trial (KAT) design features, baseline characteristics, and two-
year functional outcomes after alternative approaches to knee replacement.
J Bone Joint Surg Am. 2009;91:134–41.
24. Dakin H, Gray A, Fitzpatrick R, MacLennan G, Murray D, Group KT. Rationing
of total knee replacement: a cost-effectiveness analysis on a large trial data
set. BMJ Open. 2012;2, e000332.
25. Lack D, Ries M, Sack K, Fong C. Psychological Aspects of Total Joint
Arthroplasty. Indep Pract. 2010;30:63–6.
26. Yohannes AM, Caton S. Management of depression in older people with
osteoarthritis: a systematic review. Aging Ment Health. 2010;14:637–51.
doi:10.1080/13607860903483094.
27. Zhang W, Doherty M, Peat G, Bierma-Zeinstra SM, Arden N, Bresnihan B,
et al. EULAR evidence based recommendations for the diagnosis of knee
osteoarthritis. Ann Rheum Dis. 2010;69:483–9.
28. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta
Psychiatr Scand. 1983;67:361–70.
29. Axford J, Butt A, Heron C, Hammond J, Morgan J, Alavi A, et al. Prevalence
of anxiety and depression in osteoarthritis: use of the Hospital Anxiety and
Depression Scale as a screening tool. Clin Rheumatol. 2010;29:1277–83.
30. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital
Anxiety and Depression Scale: an updated literature review. J Psychosom
Res. 2002;52:69–77.
31. Bellamy N. WOMAC Osteoarthritis Index User Guide. Version V. Brisbane;
2002.
32. Hawker G. Measure of Intermittent and Constant Osteoarthritis Pain: ICOAP -
User’s Guide. 2010. http://oarsi.org/sites/default/files/docs/2013/icoap_
users_guide_07072010.pdf. Accessed 20 Jan 2016.
33. Beck A, Steer R, Brown GK. Manual for the Beck Depression Inventory-II. San
Antonio: Psychological Corporation; 1996.
34. Beck A, Steer R. Beck Anxiety Inventory Manual. San Antonio: The
Psychological Corporation. Harcourt Brace & Company; 1993.
35. Group TE. EuroQol-a new facility for the measurement of health-related
quality of life. Health Policy. 1990;16:199–208.
36. Moreton B, Wheeler M, Walsh D, Lincoln N. Rasch analysis of the
intermittent and constant osteoarthritis pain (ICOAP) scale. Osteoarthritis
Cartilage. 2012;20:1109–15.
das Nair et al. Trials  (2016) 17:54 Page 10 of 11
37. British Medical Association, NHS England, NHS Employers 2014/15 General
Medical Services (GMS) Contract Quality and Outcomes Framework (QOF).
Guidance for GMS Contract. 2014/15. http://www.bma.org.uk/-/media/files/
pdfs/practical%20advice%20at%20work/contracts/gpqofguidance2014-15.
pdf. Accessed 20 January 2016.
38. Julious SA. Sample size of 12 per group rule of thumb for a pilot study.
Pharm Stat. 2005;4:287–91.
39. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial
approach to chronic pain: scientific advances and future directions. Psychol
Bull. 2007;133:581.
40. Morley S. Efficacy and effectiveness of cognitive behaviour therapy for
chronic pain: Progress and some challenges. Pain. 2011;152(3 Suppl):S99–106.
41. Team GPM. Gloucester Pain Management Training Manual. 2nd ed.
Gloucester: Gloucester Royal Infirmary; 1998.
42. Guest G, Bunce A, Johnson L. How many interviews are enough? An
experiment with data saturation and variability. Field Methods. 2006;18:59–82.
43. Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP,
et al. What is an adequate sample size? Operationalising data saturation for
theory-based interview studies. Psychol Health. 2010;25:1229–45.
44. Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong
S, et al. Evaluation of an adjustment group forpeople with multiple sclerosis
and lowmood: a randomized controlled trial. Mult Scler J. 2011;17:1250–7.
45. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In:
Bryman A, Burgess R, editors. Analysing qualitative data. London: Routledge;
1993. p. 173–94.
46. Ritchie J, Lewis J. Qualitative Research Practice: A Guide for Social Science
Students and Researchers. London: Sage; 2003.
47. Pope C, Ziebland S, Mays N. Qualitative research in healthcare: analysing
qualitative data. British Med J. 2000;320:114–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
das Nair et al. Trials  (2016) 17:54 Page 11 of 11
